Why Age 70+ Shouldn't Rule Out Genetic Testing Study Reference: Gynecologic Oncology | Retrospective Registry Study  The Bottom Line Ovarian cancer is predominantly a disease of older adults, yet women aged 70 and older are far less likely to receive germline genetic testing. This study of over 113,000 patients reveals that 6.6% of patients aged 70+ carry actionable, high-risk genetic mutations . Older women were 1.5 times less likely to report a family history of cancer . Relying on family history to decide who gets genetic testing in this age group leaves a significant number of mutation carriers unidentified, missing crucial opportunities for targeted therapies and family screening. Key Findings at a Glance Significant Mutation Rate: While overall variant rates decrease with age, nearly 1 in 15 women aged 70+ with ovarian cancer still carries an actionable germline mutation. Family History Unreliable: Older patients are significantly less likely to have a documented family ...

 Look for High Blood Sugar Before Surgery Study Reference: Obstetrical & Gynecological Survey | Systematic Review The Bottom Line Many women undergo gynaecologic cancer surgery with unmanaged high blood sugar, diabetes, or prediabetes. Up to half of people with diabetes don't know they have it. This comprehensive review highlights that an elevated HbA1c (a marker showing average blood glucose over the previous three months) before surgery directly increases the risk of surgical site infections, wound breakdown, delayed healing, and shorter overall survival for ovarian cancer patients. Additionally, peri-operative high blood glucose is directly linked to Deep Vein Thrombosis (DVT). Screening and managing blood sugar before surgery is vital to improve surgical recovery and safety. Key Findings  The Hidden Risk: Around 1 in 3 adults have prediabetes, and roughly 50% of people with type 2 diabetes remain undiagnosed. Many patients enter major cancer surgery with unrecognise...

Reading Between the Lines: Spotting Hype in Ovarian Cancer Research Case Study: Institutional Research Feature ( Alliance for Cancer Gene Therapy , 2026) The Bottom Line In the era of AI-generated content and non-profit fundraising PR, science stories increasingly contain dramatic narratives, smooth promises, and misleading medical terms. A recent feature on an early-stage, 3-part treatment concept (combining a virus, modified immune cells, and specialised antibodies) shows how good ideas are represented as fact. For support nurses, learning to spot this misrepresentation is essential—not only when evaluating new literature, but to help patients navigate the gap between laboratory hopes and clinical reality. How Science PR Distorts the Truth What the Article Says The Clinical Reality Dramatic Storytelling (e.g., "Storming the fortress," "saboteurs behind enemy lines") Over-simplification. Real immune responses are complex, unpredictable chemical interactions, not ...

Emotional Distance in Ovarian Cancer Care: Why Clinicians Retreat into the Biomedical Study: Qualitative Research Study ( Frontiers in Oncology , July 2026) | Access Full Study via Frontiers in Oncology The Bottom Line In ovarian cancer management, a patient’s sense of ownership, hope, and quality of life depends heavily on empathetic communication with their care team. However, this qualitative study examining how gynaecologists interact with ovarian cancer patients reveals a stark reality: when faced with the high mortality and recurring nature of the disease, clinicians frequently retreat into objective biomedical assessments (tumour markers, scan outputs, drug choices) while maintaining emotional distance as a self-preservation strategy. Recognising this dynamic helps support nurses understand why medical consultations often feel purely technical, highlighting the critical role nurses play in filling the emotional and holistic care gap. Key Study Insig hts Focusing on the Di...

Ovarian Clear Cell Cancer Is Different: Dual Immunotherapy Signals Promise Study: Phase II Trial of Combination Nivolumab plus Ipilimumab ( PubMed ID: 40608313 / MoST-CIRCUIT) | Access Abstract via PubMed The Bottom Line Ovarian Clear Cell Cancer (OCCC) is a distinct, uncommon type of ovarian cancer—making up about 5% to 10% of cases in Western populations (and up to 15–20% in Asian cohorts). Unlike the more common serous types, clear cell tumours are notoriously resistant to standard platinum-based chemotherapy, leaving advanced cases with a poor 5-year survival rate of ~20%. Driven by unique molecular features—including underlying DNA repair deficiencies—OCCC is an ideal target for personalised immunotherapy. Early data from an Australian-led trial evaluating a dual drug combination (Nivolumab + Ipilimumab) shows encouraging response rates in this hard-to-treat group. Disease Profile & Trial Snapshot The Clinical Hurdle: Clear cell tumours often affect younger women and freque...

Commercial Liquid Biopsy for Early Detection: Ethical Realities & Specificity Defects Report: Guardian Australia Analysis on Commercial Liquid Biopsies | Access Full Report via The Guardian The Bottom Line Direct-to-consumer advertising is currently marketing a $1,495 out-of-pocket liquid biopsy test (circulating tumour DNA) to Australian women for asymptomatic ovarian cancer. While early detection remains a critical goal, health leaders—including the Ovarian Cancer Research Foundation (OCRF)—warn that commercially offering this unapproved TGA test carries major ethical concerns and severe diagnostic limitations. With a sensitivity of ~78% and a specificity of ~94%, the test simultaneously misses a quarter of true cancers while generating thousands of false alarms in healthy women. The Two-Way Diagnostic Flaw ┌─────────────────────────────────────────────────────────────────────────┐ │ COMMERCIAL TEST PROFILE │ ├────────────────────...